🇺🇸 FDA
Pipeline program

Sublingual film containing Dexmedetomidine (BXCL501)

BXCL501-302

Phase 3 small_molecule completed

Quick answer

Sublingual film containing Dexmedetomidine (BXCL501) for Agitation Associated With Bipolar Disorder is a Phase 3 program (small_molecule) at BioXcel Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
BioXcel Therapeutics
Indication
Agitation Associated With Bipolar Disorder
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials